Moderna Wins Key Patent Case, Shares Jump Almost 16% to $35.21

Key moments

Moderna Gains Big on Court Ruling, Rivals Pfizer and BioNTech Face Damages

Moderna’s stock price soared Wednesday, fueled by a favorable ruling in a German patent dispute concerning its flagship COVID-19 vaccine technology. The company secured a significant legal win against pharmaceutical giants Pfizer and BioNTech, driving its shares up nearly 16% in a single trading session, dramatically outpacing the broader market’s 1.1% gain.

The Düsseldorf court’s decision declared that Pfizer and BioNTech infringed on Moderna’s patent related to mRNA technology, specifically EP 3 590 949 and EP 3 718 565, which cover key aspects of their Comirnaty vaccine. Moderna had filed infringement suits in August 2022, alleging the rivals’ vaccine utilized its patented ribonucleic acids and respiratory virus vaccine technology.

Notably, Moderna isn’t seeking to pull Comirnaty from the market or halt future sales. Instead, the company is pursuing financial damages for sales occurring after March 8, 2022. The court has ordered Pfizer and BioNTech to disclose earnings derived from the patent’s use, which will serve as the basis for calculating the compensation owed to Moderna.

While the ruling is subject to appeal, it represents a substantial legal victory for Moderna and strengthens its intellectual property portfolio. The substantial compensatory payments expected from Pfizer and BioNTech will directly boost Moderna’s financial standing. Furthermore, this court decision sets a precedent that could influence future patent disputes, potentially providing Moderna with leverage in similar cases. The German court’s decision is a clear affirmation of Moderna’s intellectual property rights and reinforces the value of its core mRNA technology. Neither Moderna, Pfizer, nor BioNTech have issued public comments regarding the ruling.